Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
J Clin Pharm Ther ; 43(1): 45-51, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28833305

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Second-line therapy (SLT) trials in relapsed/refractory multiple myeloma (RRMM) report superior outcomes with triplet combinations. We sought to determine factors associated with triplet SLT in routine practice. METHODS: A retrospective cohort with claims for MM between 01/01/2008 and 03/31/2015 was grouped by 1-2 ("doublet") or 3+ ("triplet") agent therapy. Charlson comorbidity index (CCI) and disability status; CRAB symptoms (hypercalcaemia, renal/bone disease, anaemia); and relapse risk were determined. RESULTS: Among 623 patients, the triplet group (n=146 [23%]) was younger (65.2 vs 69.8 years) and more likely to have high-risk relapse (67% vs 50%), CRAB symptoms (94.5% vs 81.1%), triplet first-line treatment (75% vs 51%) and frontline stem cell transplant (38% vs 20%) (P<0.001 for all). In multivariate analyses, CRAB symptoms (OR: 3.22, 95% CI: 1.47, 7.10), high-risk relapse (OR: 1.71, 95% CI: 1.12, 2.62) and prior triplet therapy (OR: 2.16, 95% CI: 1.38, 3.40), but neither CCI nor disability, were associated with triplet SLT. A trend towards triplets among younger patients (<65 vs >75 years, OR: 1.73, 95% CI: 0.99, 3.04) was observed. WHAT IS NEW AND CONCLUSION: The majority of patients did not receive triplet regimens. Treatment selection with triplet therapy for RRMM should carefully consider comorbidities and patient-specific characteristics.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Neoplasm Recurrence, Local/drug therapy , Aged , Female , Humans , Male , Retrospective Studies
2.
Cogn Affect Behav Neurosci ; 17(1): 174-184, 2017 02.
Article in English | MEDLINE | ID: mdl-27722836

ABSTRACT

Although we encounter numerous expressive faces on a daily basis, those that are not aimed at us will often be disregarded. Facial expressions aimed at our direction appear far more relevant and evoke an engaging affective experience, while the exact same expressions aimed away from us may not. While the importance of expression directionality is intuitive and commonplace, the neural mechanisms underlying this phenomenon are largely unknown. In the current study we measured EEG mu rhythm suppression, an established measure of mirror neuron activity, while participants viewed short video clips of dynamic facial expressions. Critically, the videos portrayed facial emotions which turned towards or away from the viewer, thus manipulating their degree of social relevance. Mirroring activity increased as a function of social relevance such that expressions turning toward the viewer resulted in increased sensorimotor activation (i.e., stronger mu suppression) compared to identical expressions turning away from the viewer. Additional analyses confirmed that expressions turning toward the viewer were perceived as more relevant and engaging than expressions turning away from the viewer, a finding not explained by perceived intensity or recognition accuracy. Mirror sensorimotor mechanisms may play a key role in determining the relevance of perceived facial expressions.


Subject(s)
Brain/physiology , Facial Recognition/physiology , Interpersonal Relations , Motion Perception/physiology , Social Perception , Analysis of Variance , Electroencephalography , Emotions/physiology , Facial Expression , Female , Fourier Analysis , Humans , Male , Neuropsychological Tests , Orientation , Photic Stimulation , Wavelet Analysis , Young Adult
3.
Ann Oncol ; 27(1): 172-8, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26449391

ABSTRACT

BACKGROUND: To establish the role of antiemetic therapy with neurokinin-1 (NK1) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.) fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with non-AC MEC. PATIENTS AND METHODS: In this international, phase III, double-blind trial, adult cancer subjects scheduled to receive ≥1 non-AC MEC on day 1 were randomized to a regimen comprising single-dose i.v. fosaprepitant 150 mg or placebo along with ondansetron and dexamethasone on day 1; control regimen recipients received ondansetron on days 2 and 3. Primary end points were the proportion of subjects achieving a complete response (CR; no vomiting and no use of rescue medication) in the delayed phase (25-120 h after MEC initiation) and safety. Secondary end points included CR in the overall and acute phases (0-120 and 0-24 h after MEC initiation, respectively) and no vomiting in the overall phase. Nausea and the Functional Living Index-Emesis were assessed as exploratory end points. RESULTS: The fosaprepitant regimen improved CR significantly in the delayed (78.9% versus 68.5%; P < 0.001) and overall (77.1% versus 66.9%; P < 0.001) phases, but not in the acute phase (93.2% versus 91.0%; P = 0.184), versus control. In the overall phase, the proportion of subjects with no vomiting (82.7% versus 72.9%; P < 0.001) and no significant nausea (83.2% versus 77.9%; P = 0.030) was also significantly improved with the fosaprepitant regimen. The fosaprepitant regimen was generally well tolerated. CONCLUSION: Single-dose fosaprepitant added to a 5-HT3 RA and dexamethasone was well tolerated and demonstrated superior control of CINV (primary end point achieved) associated with non-AC MEC. This is the first study to evaluate NK1 RA therapy as an i.v. formulation in a well-defined non-AC MEC population. CLINICALTRIALSGOV: NCT01594749 (https://clinicaltrials.gov/ct2/show/NCT01594749).


Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Lung Neoplasms/drug therapy , Morpholines/therapeutic use , Nausea/prevention & control , Vomiting/prevention & control , Antineoplastic Agents/therapeutic use , Double-Blind Method , Female , Humans , Male , Middle Aged , Nausea/chemically induced , Treatment Outcome , Vomiting/chemically induced
4.
Leukemia ; 24(7): 1350-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20508619

ABSTRACT

This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and to assess the safety and efficacy of this combination in untreated multiple myeloma patients. Cohorts of three to six patients received a cyclophosphamide dosage of 100, 200, 300, 400 or 500 mg/m(2) (on days 1 and 8) plus bortezomib 1.3 mg/m(2) (on days 1, 4, 8 and 11), dexamethasone 40 mg (on days 1, 8 and 15) and lenalidomide 15 mg (on days 1-14), for eight 21-day induction cycles, followed by four 42-day maintenance cycles (bortezomib 1.3 mg/m(2), on days 1, 8, 15 and 22). The MTD was the cyclophosphamide dose below which more than one of six patients experienced a dose-limiting toxicity (DLT). Twenty-five patients were treated. Two DLTs were seen, of grade 4 febrile neutropenia (cyclophosphamide 400 mg/m(2)) and grade 4 herpes zoster despite anti-viral prophylaxis (cyclophosphamide 500 mg/m(2)). No cumulative hematological toxicity or thromboembolic episodes were reported. The overall response rate was 96%, including 20% stringent complete response (CR), 40% CR/near-complete response and 68% >or=very good partial response. VDCR is well tolerated and highly active in this population. No MTD was reached; the recommended phase 2 cyclophosphamide dose in VDCR is 500 mg/m(2), which was the highest dose tested.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Multiple Myeloma/drug therapy , Neoplasm Recurrence, Local/diagnosis , Aged , Boronic Acids/administration & dosage , Bortezomib , Cohort Studies , Cyclophosphamide/administration & dosage , Dexamethasone/administration & dosage , Female , Follow-Up Studies , Humans , Lenalidomide , Male , Maximum Tolerated Dose , Middle Aged , Multiple Myeloma/pathology , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Pyrazines/administration & dosage , Remission Induction , Survival Rate , Thalidomide/administration & dosage , Thalidomide/analogs & derivatives , Treatment Outcome
5.
Int J Radiat Oncol Biol Phys ; 57(1): 166-71, 2003 Sep 01.
Article in English | MEDLINE | ID: mdl-12909229

ABSTRACT

PURPOSE: In patients in whom bone marrow transplantation (BMT) fails, recurrence often occurs at sites known to have contained disease before initiating BMT. The purpose of this study was to find the maximal tolerable dose of locoregional irradiation (LRT) between 1000 and 2000 cGy that could be integrated with our Cytoxan-total body irradiation (TBI) BMT conditioning regimen in the treatment of lymphoma. METHODS AND MATERIALS: Patients had Hodgkin's or non-Hodgkin's lymphoma in chemotherapy-refractory relapse. All patients received LRT to a maximum of three sets of fields encompassing either all current or all previously known sites of disease. Cytoxan-TBI consisted of cyclophosphamide 50 mg/kg daily for 4 days followed by TBI of 1200 cGy given in four fractions. RESULTS: Twenty-one patients were enrolled. Radiation Therapy Oncology Group Grade 3 in-field acute toxicity was observed in 1 patient at each dose level up to 1500 cGy and in 3 of 6 patients receiving 2000 cGy. Clinically evident late toxicities were limited to hypothyroidism and one second malignancy occurring outside the LRT fields. CONCLUSION: Low-dose-rate, LRT with concurrent Cytoxan-TBI before BMT has acceptable rates of in-field toxicity for doses up to 1500 cGy in five fractions. This regimen safely permits the use of a total combined radiation dose of up to 2700 cGy during 2 weeks, with encouraging in-field response rates in treatment-refractory patients.


Subject(s)
Cyclophosphamide/therapeutic use , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/radiotherapy , Maximum Tolerated Dose , Whole-Body Irradiation/methods , Adolescent , Adult , Aged , Bone Marrow Transplantation , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Dose-Response Relationship, Radiation , Hodgkin Disease/mortality , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/therapy , Middle Aged , Radiotherapy Dosage , Treatment Outcome , Whole-Body Irradiation/adverse effects
6.
Bone Marrow Transplant ; 31(12): 1073-80, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12796786

ABSTRACT

T-cell depletion of the marrow graft using counterflow centrifugal elutriation reduces the risk of graft-versus-host disease (GVHD). However, because of high rates of graft failure and relapse, elutriation alone has not improved survival. We have carried out a phase II clinical trial in 54 pediatric patients to determine if CD34+ selection to rescue pluripotent stem cells from the small lymphocyte fraction improves engraftment. The processed grafts contained a mean of 5.5 x 10(7) cells/kg IBW, 4.7 x 10(6) CD34+ cells/kg IBW, and 6.3 x 10(5) CD3+cells/kg IBW. Patients achieved an ANC >500 at a median of 16 days and platelet count >20 000 at a median of 28 days. The incidence of clinically significant GVHD was 19%. In total, 10 patients enrolled in this study experienced graft failure, with eight of the 14 patients transplanted for nonmalignant indications failing to engraft stably. Graft failure was statistically significantly associated with nonmalignant diagnosis (P<0.001), but was not associated with CMV seropositivity, donor gender, or cell counts of the allograft. We conclude that although time to engraftment is similar to that seen with unmanipulated grafts, graft failure remains a significant problem in patients with hereditary, nonmalignant diseases. Future efforts will seek to preserve the benefits of elutriation with CD34+ selection by increasing immune ablation of the preparative regimen and/or increasing posttransplant immune suppression.


Subject(s)
Bone Marrow Transplantation/methods , Adolescent , Adult , Antigens, CD34/metabolism , Bone Marrow Transplantation/adverse effects , Cell Separation , Child , Female , Graft Survival , Graft vs Host Disease/prevention & control , Hematologic Diseases/mortality , Hematologic Diseases/therapy , Humans , Male , Neoplasms/mortality , Neoplasms/therapy , Pluripotent Stem Cells/transplantation , Severe Combined Immunodeficiency/therapy , Survival Rate , Transplantation, Homologous , beta-Thalassemia/therapy
7.
J Clin Oncol ; 19(23): 4314-21, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11731514

ABSTRACT

PURPOSE: To evaluate the long-term outcome after allogeneic (allo) and autologous (auto) blood or marrow transplantation (BMT) in patients with relapsed or refractory Hodgkin's lymphoma (HL). PATIENTS AND METHODS: We analyzed the outcome of 157 consecutive patients with relapsed or refractory HL, who underwent BMT between March 1985 and April 1998. Patients

Subject(s)
Blood Transfusion , Bone Marrow Transplantation , Hodgkin Disease/therapy , Adolescent , Adult , Baltimore , Child , Disease-Free Survival , Female , Graft vs Host Disease , Hodgkin Disease/mortality , Humans , Longitudinal Studies , Male , Middle Aged , Recurrence , Survival Analysis , Transplantation, Autologous , Transplantation, Homologous , Treatment Outcome
8.
J Clin Oncol ; 19(17): 3771-9, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11533101

ABSTRACT

PURPOSE: Although high-dose chemotherapy supported by autologous peripheral-blood progenitor-cell (PBPC) transplantation improves response rates and survival for patients with multiple myeloma, all patients eventually develop progressive disease after transplantation. It has been hypothesized that depletion of malignant plasma cells from autografts may improve outcome by reducing infused cells contributing to relapse. PATIENTS AND METHODS: A randomized phase III study using the CEPRATE SC System (Cellpro, Bothell, WA) to enrich CD34(+) autograft cells and passively purge malignant plasma cells was completed in 190 myeloma patients randomized to receive an autograft of CD34-selected or unselected PBPCs. RESULTS: After CD34 selection, tumor burden was reduced by 1.6 to 6.0 logs (median, 3.1), with 54% of CD34-enriched products having no detectable tumor. Median time to count recovery, number of transfusions, transplantation-related mortality, and days in hospital were equivalent between the two transplantation arms. With a median follow-up of 37 months, 33 patients (36%) in the selected and 34 patients (35%) in the unselected arm had died (P =.784). Median overall survival in the selected arm was reached at 50 months and is not reached at this time in the unselected arm (P =.78). Median disease-free survival was 100 versus 104 weeks (P =.82), with 67% of patients in the selected arm and 66% of patients in the unselected arm relapsing. CONCLUSION: This phase III trial demonstrates that although CD34 selection significantly reduces myeloma cell contamination in PBPC collections, no improvement in disease-free or overall survival was achieved.


Subject(s)
Antigens, CD34/analysis , Bone Marrow Purging/methods , Multiple Myeloma/therapy , Adult , Aged , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Male , Middle Aged , Multiple Myeloma/immunology , Multiple Myeloma/mortality , Neoplastic Cells, Circulating/immunology , Polymerase Chain Reaction , Proportional Hazards Models , Survival Rate
10.
Cytotherapy ; 3(6): 483-8, 2001.
Article in English | MEDLINE | ID: mdl-11953032

ABSTRACT

BACKGROUND: T-cell depletion of allografts markedly reduces the incidence of GvHD following BMT. The approach taken at our Center has utilized the physical separation method of counterflow centrifugal elutriation (CCE), augmented by recovery of stem cells from lymphocyte-rich fractions by immunoaffinity selection of CD34(+) stem cells. We wanted to compare the performance characteristics of three commercially available selection devices, as well as the clinical outcomes of patients who received allografts engineered by the different devices. METHODS: BM allografts were prepared for patients undergoing BMT for hematologic malignancies. BM cells were separated into lymphocyte-rich and lymphocyte-depleted fractions using CCE, followed by recovery of CD34(+) cells from the lymphocyte-rich fraction using one of three immunoselection devices [CellPro CEPRATE, Nexell Isolex 300i (software version 2.5) and AmCell CliniMACS]. Allografts consisted of the lymphocyte-depleted fraction plus the CD34-selected fraction. RESULTS: Yields of CD34(+) cells were comparable for the three devices. However, there were significant differences in purity (CEPRATE < Isolex 300i < CliniMACS) and time from start of fractionation to infusion (CEPRATE < CliniMACS < Isolex 300i). More technical problems were encountered with the Isolex 300i device. Allograft compositions were comparable. Transplant outcomes (engraftment and incidence of GvHD) also were comparable. DISCUSSION: Qualitatively and quantitatively, allografts prepared with the CEPRATE, Isolex 300i (v 2.5) and CliniMACS devices should be considered comparable for use in this setting and probably also for direct T-cell depletion of BM.


Subject(s)
Antigens, CD34/analysis , Bone Marrow Transplantation , Cell Separation/instrumentation , Hematopoietic Stem Cells , Lymphocyte Depletion , T-Lymphocytes , Adolescent , Adult , Bone Marrow Transplantation/instrumentation , Bone Marrow Transplantation/methods , Cell Separation/methods , Female , Flow Cytometry , Humans , Male , Middle Aged , Transplantation, Homologous
11.
Cytotherapy ; 3(1): 11-8, 2001.
Article in English | MEDLINE | ID: mdl-12028839

ABSTRACT

BACKGROUND: A PBSC graft containing 4-5 x 10(6) CD34(+) cells/kg is considered optimal in terms of durable engraftment. Tracking CD34 kinetics via point-of-care testing during PBSC mobilization could determine which (and when) patients will yield an optimal product. We evaluated whether microvolume fluorimetry (MVF) would be useful in optimizing PBSC mobilization/harvest and if it will shorten our standard 6 h collection. METHODS: Absolute CD34 values were obtained using the IMAGN 2000 and STELLer CD34 assay (50 microL sample volume). Peripheral blood (PB) CD34 values from 30 patients undergoing PBSC mobilization were used to generate a PB CD34-based algorithm that would predict collection day/duration of apheresis. The algorithm was then used prospectively to collect PBSC products on 50 hematologic malignancy (HM) patients. RESULTS: Using the algorithm, patients were assigned to either a 6 (11-20 CD34/microL), 4 (21-49 CD34/microL) or 2 (> or = 50 CD34/microL) h collection. Patients with a CD34 value < or = 10/microL were re-tested. All patients (n = 43) predicted to mobilize reached the optimal CD34 (4-5 x 10(6)/kg) value with 1.0 apheresis procedure; seven patients had < or = 10/microL (nonmobilizers). The majority (75%) had apheresis charges decreased by 33-66%; 47% only required a 2 h procedure and 28% required 4 h. All patients demonstrated rapid trilineage engraftment. DISCUSSION: Absolute PB CD34 measurement using MVF offers a rapid and reliable approach to obtaining optimal PBSC products with minimal technical expertise. Although not a replacement for conventional flow cytometry, it meets the requirements for a point-of-care procedure.


Subject(s)
Antigens, CD34/analysis , Blood Component Removal/methods , Erythroid Precursor Cells/transplantation , Hematopoietic Stem Cell Mobilization/methods , Point-of-Care Systems , Algorithms , Fluorometry/methods , Hematologic Neoplasms/blood , Hematologic Neoplasms/therapy , Humans , Time Factors , Treatment Outcome
12.
Cancer Control ; 8(6 Suppl 2): 78-87, 2001.
Article in English | MEDLINE | ID: mdl-11760563

ABSTRACT

Although multiple myeloma is sensitive to both chemotherapy and RT, it remains incurable at present. However, treatment algorithms based on published data, as well as clinical experience, can be developed to optimize therapy. This includes not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.


Subject(s)
Multiple Myeloma/diagnosis , Multiple Myeloma/therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Hematopoietic Stem Cell Transplantation , Humans , Multiple Myeloma/complications , Neoplasm Staging , Plasmacytoma/diagnosis , Plasmacytoma/therapy , Prognosis , Radiotherapy, Adjuvant , Salvage Therapy , Transplantation, Autologous , Transplantation, Homologous , Treatment Outcome
13.
Biol Blood Marrow Transplant ; 7(10): 561-7, 2001.
Article in English | MEDLINE | ID: mdl-11760088

ABSTRACT

PURPOSE: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). PATIENTS AND METHODS: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. RESULTS: The incidence of acute GVHD grade >2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and <2 prior treatments; rates of EFS were 0% (95% CI, 0%-0%) and 79% (95% CI, 47%-93%), respectively. CONCLUSION: These data show that, with T-cell depletion, the TRM and relapse rates are modest for patients with sensitive disease and <2 prior treatment courses. Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease.


Subject(s)
Bone Marrow Transplantation/mortality , Lymphoma, Mantle-Cell/therapy , Lymphoma, Non-Hodgkin/therapy , Adult , Bone Marrow Transplantation/methods , Female , Graft vs Host Disease , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Lymphocyte Depletion , Lymphoma, Mantle-Cell/mortality , Lymphoma, Non-Hodgkin/mortality , Male , Middle Aged , Survival Rate , Transplantation, Homologous , Treatment Outcome
14.
Biol Blood Marrow Transplant ; 6(6): 628-32, 2000.
Article in English | MEDLINE | ID: mdl-11128813

ABSTRACT

Peripheral blood stem cell grafts from patients with lymphoma are often contaminated with neoplastic cells. Administration of a lymphoma-specific monoclonal antibody before collecting stem cells may be one way of reducing the contamination. Similarly, an antibody after transplantation at a time of minimal residual disease may increase the efficacy of the procedure. The objective of this study was to determine the safety of using rituximab as both an in vivo purging agent and a posttransplantation adjuvant. Eligible patients with lymphoma received 375 mg/m2 rituximab intravenously IV) on day 1, 2.5 g/m2 cyclophosphamide IV on day 4, and 10 microg/kg per day filgrastim starting on day 5 and continuing until completion of leukapheresis. Patients subsequently received a standard preparative regimen and then received 375 mg/m2 rituximab IV 7 days after platelet independence was achieved. Twenty-five patients (14 men, 11 women; median age, 51 years) were enrolled. Of the 25 patients, 23 received transplants after at least 2.0 x 10(6) CD34+ cells/kg were harvested. As determined with a sensitive polymerase chain reaction assay, 6 of 7 stem cell products tested were free of tumor contamination. All patients engrafted promptly, and the rituximab infusions were well tolerated. Transient neutropenia of uncertain etiology occurred in 6 patients a median of 99.5 days post-transplantation. An additional patient developed progressive pancytopenia. Rituximab used as an in vivo purging agent and adjuvant immunotherapy with peripheral blood stem cell transplantation for non-Hodgkin's lymphoma is a well-tolerated regimen. However, the ultimate determination of efficacy will require the results of ongoing studies.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/administration & dosage , Hematopoietic Stem Cell Transplantation , Immunotherapy , Lymphoma, Non-Hodgkin/therapy , Adult , Aged , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Agents/immunology , Bone Marrow Purging , Combined Modality Therapy , Female , Humans , Lymphoma, Non-Hodgkin/immunology , Male , Middle Aged , Rituximab , Transplantation, Autologous , Treatment Outcome
15.
Br J Cancer ; 83(11): 1405-11, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11076645

ABSTRACT

The purpose of the present study was to investigate the impact of the use of peripheral blood progenitor cells (PBPCs) on the induction of autologous graft-versus-host disease (GVHD) in patients with advanced breast cancer. 14 women with stage IIIB and 36 women with stage IV breast cancer received cyclosporine (CsA) 2.5 mg kg-1 i.v. daily, d 0-28, and interferon-gamma (IFNg) 0.025 mg/m2 s.c. qod, d7-28, following PBPC-T +/- bone marrow transplantation (BMT). Preceding high-dose chemotherapy consisted of cyclophosphamide 6 g/m2 and thiotepa 800 mg/m2. Histologically proven > or = grade II cutaneous GVHD was induced in18/50 (36%) of patients and was independent of the source of haematopoietic support. In vitro studies showed that post-transplant, 76% of patients had developed auto-cytotoxicity against their own pre-transplant PHA-lymphoblasts. A significant correlation between the occurrence of GVHD > or = grade II and cytolysis was observed in the NK cell-line K562 and the T47D breast cancer cell-line. With a median follow-up of 2(1/2) years, the overall survival (OS) is 58%, the disease-free survival (DFS) 26%, both independent of the development of GVHD and similar to what has been observed in other studies on high-dose chemotherapy in advanced breast cancer. It therefore remains unclear whether the induction of autologous GVHD with the occurrence of auto-cytotoxic lymphocytes can result in an anti-tumour effect in this group of patients.


Subject(s)
Bone Marrow Transplantation/immunology , Breast Neoplasms/immunology , Breast Neoplasms/therapy , Graft vs Host Disease/immunology , Graft vs Tumor Effect/immunology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/immunology , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclosporine/adverse effects , Cyclosporine/therapeutic use , Cytotoxicity, Immunologic , Dose-Response Relationship, Drug , Female , Graft vs Host Disease/chemically induced , Humans , Immunosuppressive Agents/therapeutic use , Interferon-gamma/therapeutic use , Killer Cells, Natural/immunology , Lymphocytes/immunology , Middle Aged , Phytohemagglutinins/pharmacology , Survival Analysis , Thiotepa/administration & dosage , Thiotepa/adverse effects
16.
Semin Oncol ; 27(2 Suppl 5): 15-21, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10877046

ABSTRACT

Improvements in supportive care, antimicrobials, immunosuppressant therapy, and health care delivery have shifted the emphasis in hematopoietic stem cell transplantation toward raising cure rates and improving the quality of life in the years that follow transplantation. Many large centers have significantly reduced the morbidity of allogeneic transplantation by effecting a decrease in acute and chronic graft-versus-host disease. Extension of this modality through the use of unrelated donors, peripheral blood stem cell products, and HLA-mismatched family members has again introduced significant posttransplantation complications. Conversely, the posttransplantation morbidity of autologous transplantation is minimal, but the chances of remaining in long-term remission are still inferior to those afforded by allogeneic hematopoietic stem cell transplantation. One approach developed to reduce these long-term complications is referred to as "graft engineering." Through the use of successive clinical protocols, hematopoietic grafts and host immune properties can be manipulated in a stepwise fashion using several outcome parameters to judge efficacy. This report details one center's experiences with graft engineering over 12 consecutive years of clinical trials and speculates on future approaches that may supplant transplantation in the new millennium.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Acute Disease , Anti-Infective Agents/therapeutic use , Bone Marrow Purging , Chronic Disease , Clinical Protocols , Graft vs Host Disease/prevention & control , HLA Antigens/immunology , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Histocompatibility/immunology , Humans , Immunosuppressive Agents/therapeutic use , Lymphocyte Depletion , Quality of Life , T-Lymphocytes/immunology , Transplantation Conditioning , Transplantation Immunology , Transplantation, Autologous , Transplantation, Homologous , Treatment Outcome
17.
Blood ; 95(7): 2289-96, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10733498

ABSTRACT

Gender differences in vascular thromboses are well known, and there is evidence that platelets may be involved in these differences and that sex hormones affect platelet function. We characterized the expression of the estrogen receptor alpha (ER alpha), estrogen receptor beta (ER beta), progesterone receptor (PR), and androgen receptor (AR) in the megakaryocyte lineage. Megakaryocytes generated ex vivo from normal human CD34(+) stem cells contained RNA for ER beta and AR, which increased with cell differentiation. Platelets and human erythroleukemia (HEL) cells also contained ER beta and AR transcripts. No ER alpha or PR messenger RNA or protein was detected in the megakaryocyte lineage. Immunofluorescence microscopy showed that ER beta protein was present in glycoprotein (GP) IIb(+) megakaryocytes and the HEL megakaryocytic cell line in a predominantly cytoplasmic location. AR showed a cytoplasmic and nuclear distribution in GPIIb(+) and GPIIb(-) cells derived from CD34(+) cells and in HEL cells. Western immunoblotting confirmed the presence of ER beta and AR in platelets. Megakaryocyte and HEL AR expression was up-regulated by 1, 5, and 10 nmol/L testosterone, but down-regulated by 100 nmol/L testosterone. These findings indicate a regulated ability of megakaryocytes to respond to testosterone and suggest a potential mechanism through which sex hormones may mediate gender differences in platelet function and thrombotic diseases.


Subject(s)
Blood Platelets/metabolism , Gene Expression Regulation/drug effects , Megakaryocytes/metabolism , Receptors, Androgen/genetics , Receptors, Estrogen/genetics , Testosterone/pharmacology , Antigens, CD34/analysis , Blood Platelets/chemistry , Blotting, Western , Cell Line , Estrogen Receptor beta , Hematopoietic Stem Cells/chemistry , Humans , Megakaryocytes/chemistry , Microscopy, Fluorescence , Receptors, Androgen/analysis , Receptors, Estrogen/analysis , Tumor Cells, Cultured
18.
Bone Marrow Transplant ; 25(2): 153-60, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10673673

ABSTRACT

Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), has recently been identified within the bone marrow dendritic cells of multiple myeloma (MM) patients. This virus contains homologues to human cytokines such as IL-6 that could potentially stimulate myeloma cell growth and contribute to disease pathogenesis. Since mobilization chemotherapy may increase circulating dendritic cell numbers, we searched for HHV-8 in peripheral blood mononuclear cells (PBMCs) before and after mobilization chemotherapy given to MM patients. Furthermore, we determined if autograft purging using the CEPRATE SC device would reduce the percentage of HHV-8 infected stem cell products. Only two of the 39 PBMC samples collected prior to mobilization chemotherapy contained PCR detectable virus, yet nine of 37 PBMCs collected on the first day of leukapheresis had detectable HHV-8 (P = 0.016). HHV-8 was more frequently identified in autograft products before vs after Ceprate SC selection (40% vs 15%, P = 0.016). Although the role HHV-8 plays in myeloma pathogenesis remains unclear, these results imply that mobilization chemotherapy increases the numbers of circulating HHV-8-infected dendritic cells within the peripheral blood. In addition, CD34 selection of autograft products in MM patients may reduce the reintroduction of virally infected cells following high-dose chemotherapy. Bone Marrow Transplantation (2000) 25, 153-160.


Subject(s)
Blood Transfusion, Autologous , Dendritic Cells/virology , Hematopoietic Stem Cell Mobilization/methods , Herpesvirus 8, Human/isolation & purification , Leukocytes, Mononuclear/virology , Multiple Myeloma/therapy , Antigens, CD34/analysis , Base Sequence , Bone Marrow Purging/methods , Cohort Studies , DNA, Viral/analysis , DNA, Viral/genetics , Dendritic Cells/cytology , Hematopoietic Stem Cell Transplantation/methods , Herpesviridae Infections/blood , Herpesviridae Infections/virology , Herpesvirus 8, Human/genetics , Humans , Leukapheresis , Leukocytes, Mononuclear/cytology , Molecular Sequence Data , Multiple Myeloma/blood , Multiple Myeloma/virology , Polymerase Chain Reaction , Survival Rate , Treatment Outcome , Viral Load
20.
Blood ; 94(12): 4084-92, 1999 Dec 15.
Article in English | MEDLINE | ID: mdl-10590053

ABSTRACT

Investigation of the molecular basis of megakaryocyte (MK) and platelet biology has been limited by an inadequate source of genetically manipulable cells exhibiting physiologic MK and platelet functions. We hypothesized that ex vivo cultured MKs would exhibit agonist inducible glycoprotein (GP) IIb-IIIa activation characteristic of blood platelets and that these cultured MKs would be capable of transgene expression. Microscopic and flow cytometric analyses confirmed that human hematopoietic stem cells cultured in the presence of pegylated recombinant human MK growth and development factor (PEG-rHuMGDF) differentiated into morphologic and phenotypic MKs over 2 weeks. Cultured MKs expressed functional GPIIb-IIIa receptors as assessed by agonist inducible soluble fibrinogen and PAC1 binding. The specificity and kinetics of fibrinogen binding to MK GPIIb-IIIa receptors were similar to those described for blood platelets. The reversibility and internalization of ligands bound to MK GPIIb-IIIa also shared similarities with those observed in platelets. Cultured MKs were transduced with an adenoviral vector encoding green fluorescence protein (GFP) or beta-galactosidase (beta-gal). Efficiency of gene transfer increased with increasing multiplicities of infection and incubation time, with 45% of MKs expressing GFP 72 hours after viral infection. Transduced MKs remained capable of agonist induced GPIIb-IIIa activation. Thus, ex vivo cultured MKs (1) express agonist responsive GPIIb-IIIa receptors, (2) are capable of expressing transgenes, and (3) may prove useful for investigation of the molecular basis of MK differentiation and GPIIb-IIIa function.


Subject(s)
Gene Transfer Techniques , Megakaryocytes/physiology , Platelet Glycoprotein GPIIb-IIIa Complex/biosynthesis , Adenoviridae , Cell Differentiation , Cells, Cultured , Genetic Vectors , Humans , Megakaryocytes/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...